
    
      This study will be conducted in subjects with established Parkinson's disease in 2 parts.

      Part A will examine the tolerability, safety, and pharmacokinetics of daily doses of AZ-009
      for 5 days followed by 3 doses on each of days 6 and 7 in dose escalation through 3 cohorts

      Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of AZ-009
      compared with placebo in subjects with established Parkinson's disease experiencing regular
      OFF episodes
    
  